# Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

> **NCT02230761** · PHASE2 · COMPLETED · sponsor: **Topokine Therapeutics, Inc.** · enrollment: 90 (actual)

## Conditions studied

- Lower Eyelid Steatoblepharon (Excess Eyelid Fat)

## Interventions

- **DRUG:** XOPH5 Ointment
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02230761
- **Lead sponsor:** Topokine Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2016-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02230761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02230761, "Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02230761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*